BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23531737)

  • 21. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors.
    Pöpperl G; Helmberger T; Münzing W; Schmid R; Jacobs TF; Tatsch K
    Cancer Biother Radiopharm; 2005 Apr; 20(2):200-8. PubMed ID: 15869456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
    Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
    J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
    Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
    J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
    Jiao LR; Szyszko T; Al-Nahhas A; Tait P; Canelo R; Stamp G; Wasan H; Lowdell C; Philips R; Thillainayagam A; Bansi D; Rubello D; Limongelli P; Woo K; Habib NA
    Eur J Surg Oncol; 2007 Jun; 33(5):597-602. PubMed ID: 17433608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma.
    Kawamura E; Shiomi S; Kotani K; Kawabe J; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Enomoto M; Murakami Y; Tamori A; Kawada N
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1722-7. PubMed ID: 24730671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery.
    Lee HS; Kim HO; Hong YS; Kim TW; Kim JC; Yu CS; Kim JS
    J Nucl Med; 2014 Apr; 55(4):582-9. PubMed ID: 24549284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative p retreatment VOI analysis of liver metastases. (99m)Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT.
    Van de Wiele C; Stellamans K; Brugman E; Mees G; De Spiegeleer B; D'Asseler Y; Beels L; Maes A
    Nuklearmedizin; 2013; 52(1):21-7. PubMed ID: 23358716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
    Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
    World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
    Wong CY; Salem R; Qing F; Wong KT; Barker D; Gates V; Lewandowski R; Hill EA; Dworkin HJ; Nagle C
    J Nucl Med; 2004 Nov; 45(11):1892-7. PubMed ID: 15534060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
    Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
    J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
    Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
    Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.